Revenio Group Oyj - Changes board/management/auditors

Revenio Group Corporation: New CEO for Revenio and expansion in Management Team

Revenio Group Corporation, Stock Exchange Release, May 16, 2016 at 13:00

NEW CEO FOR REVENIO AND EXPANSION IN MANAGEMENT TEAM

Revenio Group Plc.'s long term CEO Olli-Pekka Salovaara (born 1960) will leave
his position after a transition period on January 1st, 2017 and he will continue
in the position of Executive Chairman of the Board of Icare USA Inc.'s.

Revenio Group Plc.'s Board of Directors has appointed M.Sc. Timo Hildén (born
1959) as the new Group CEO as of January 1st, 2017. Hildén has worked as the CEO
of Revenio Group's subsidiary Icare Finland since April 2012. Hildén has also
been appointed as the Segment Director of Revenio Health Tech as of May
16th, 2016.

"The strategy change we started in 2012 has progressed to the implementation
phase under Olli-Pekka Salovaara's lead and our organization is now in place to
support the set global growth objectives. Now is a good time to transfer the
position of CEO to Timo Hildén who is a strong expert in the health technology
sector. The transition period will ensure the successful implementation of the
change. It is very natural that Olli-Pekka will take the responsibility of
further embodiment of our US strategy since he is already living in the United
States. On behalf of the entire Board of Directors I wish to express our thanks
already at this stage to Olli-Pekka for the job well done," says Pekka Tammela,
Chairman of the Board, Revenio Group Plc.

"During my term of office, we have transformed a conglomerate into a successful
health tech company which has resulted the growth of Revenio's market value from
some tens of millions to 200 million euros. I have worked as the CEO of Revenio
almost for ten eventful years.  The decision to ease the work burden as of next
year has matured gradually. Timo Hildén who has successfully managed Icare
Finland, is the right person to continue the work from here on," states Olli-
Pekka Salovaara.

The Management Team of Revenio Group will be expanded as of June 1st, 2016 and
the members will be Revenio Group Plc's CEO Olli-Pekka Salovaara (until December
31, 2016), Icare Finland Ltd's CEO and Segment Director of Revenio Health
Tech Timo Hilden, Revenio Group Plc's CFO Robin Pulkkinen, Sales and Marketing
Director Tomi Karvo, Revenio Research Oy's R&D Director Ari Kukkonen and Icare
Finland Ltd's Operations Director Ari Isomäki as a new member. Also, Tiina
Olkkonen is attending Management Team meetings as an external communication
specialist and Management Team secretary. In addition, an Extended Management
Team that meets on quarterly basis is established as of June 1st, 2016,
consisting of Management Team members and the CEO of Icare USA Inc John Floyd.

For further information, please contact:
Chairman of the Board, Pekka Tammela
Tel: +358 40 503 9009
www.revenio.fi

DISTRIBUTION:
Nasdaq Helsinki
Financial Supervisory Authority (FIN-FSA)
Principal media
www.revenio.fi

The Revenio Group in brief

Revenio is a Finnish, globally operating health technology corporation whose
worldwide success is based on a strongly patented intraocular pressure
measurement technology. The Revenio Group consists of Icare Finland Oy, Revenio
Research Oy and Oscare Medical Oy, in which Revenio holds a 53% interest. The
common denominators of Revenio's business operations include screening, follow-
up and the global need to make cost savings through preventive health care.
Revenio seeks vigorous growth in health technology. Revenio aims at developing
even more efficient and easily adopted methods for the early-stage detection of
diseases with significance for public health. The focus of Revenio's screening
technology is on the early detection of glaucoma, osteoporosis, skin cancer and
asthma, and the monitoring of these during the treatment process.

In 2015, the Revenio Group's net sales totaled MEUR 20.3, with its operating
margin for continuing operations standing at 28.4%. Revenio Group Corporation is
listed on Nasdaq Helsinki.


[HUG#2012919]